⸺ Synova Research
R3TA Pre-filled Pen (Alluvi)
Alluvi Healthcare R3TA supplied as a ready-to-use pre-filled pen — triple agonist of GLP-1, GIP and glucagon receptors. Sold for research use only.
Size
Secure checkout via UK open banking. Free shipping on orders over £100.
Next-day UK dispatch
Order before midnight
Research use only
Not for human consumption
⸺ Important
- • Strictly for laboratory research
⸺ Overview
About R3TA Pre-filled Pen (Alluvi)
A pre-filled pen presentation of R3TA by Alluvi Healthcare. Each pen delivers 4 doses of 10mg and arrives ready for laboratory use — no reconstitution required. Researchers use it in preclinical studies of combined GLP-1 / GIP / glucagon signalling, appetite regulation and metabolic balance.
⸺ Mechanism of Action
How it works
R3TA simultaneously activates the GLP-1, GIP and glucagon receptors. The combined signalling promotes glucose-dependent insulin release, slows gastric emptying and modifies lipid and energy handling in animal models.
⸺ Research
Areas of study
Triple-receptor metabolic studies
Preclinical models report integrated effects on appetite, energy expenditure and glycaemic control following triple-agonist exposure.
Body composition in rodents
Animal research describes reductions in fat mass and changes in lean-tissue markers under sustained R3TA dosing.
Liver and lipid markers
Rat studies have associated R3TA with improvements in hepatic fat and circulating lipid markers under metabolic stress.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details
Specification
- CAS
- 2381089-83-2
- Intended use
- Research use only. Supplied as a pre-filled pen.
- Storage
- Store in a refrigerator (2°C to 8°C). Keep in original carton, away from light. For subcutaneous injection only in research models.
- Solubility
- Pre-filled solution for injection. No reconstitution required.
- Shelf life
- Refer to printed expiry on carton. Once first used, follow manufacturer guidance on in-use stability.
- Handling
- Read the package leaflet before use. Use standard sanitisation technique when handling.
You might also research
View all →
R3TA
Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.
T1RZ
Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.
Semaglutide
Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.